why choose us

First received: December 13, 2024

Clinical Trial: Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Healthy Subjects

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Open Label, Randomized, Parallel Drug Interaction Study to Evaluate the Effect of a CYP3A Weak Inducer Rufinamide on the Pharmacokinetics of Quizartinib in Healthy Subjects

Brief Summary: This study will evaluate the effect of CYP3A weak inducer rufinamide on the pharmacokinetics (PK) of Quizartinib in healthy subjects

Read more